Recent clinical trials in East Asia have demonstrated that oral formulations of GLP-1 receptor agonists (GLP-1RAs) can achieve approximately 13 percentage points of weight loss over 68 weeks, addressing a major barrier to their use related to patients' fear of injections. An estimated 5.8 million adolescents aged 12-17 and 11.1 million young adults aged 18-25 are considered candidates for GLP-1 drug treatment. However, new guidance from the UK's National Institute for Health and Care Excellence (NICE) advises that individuals discontinuing obesity medications such as Wegovy and Mounjaro should undergo medical check-ups for at least a year to monitor and prevent weight regain. Health professionals emphasize that while GLP-1 drugs offer an opportunity to learn healthier eating habits, ongoing support is critical, as many patients tend to regain most of the weight lost after stopping treatment. The demand for these treatments remains high within the NHS.